ERBB2 and neoplasm: At present, according to national guidelines, it is recommended that NACT be offered to patients with large tumors (T3/T4), patients with positive lymph node status in the axilla, and patients with tumors larger than 20 mm and, simultaneously, other risk factors, e.g., triple negative tumor or HER2 positivity [9, 10].